Sponsors (8)
The bill substantially expands no-cost, coordinated ALS outpatient care and strengthens trial and provider incentives — improving access and research capacity for people with ALS — while increasing federal Medicare spending and creating risks of resource shifts, access disparities for those without digital access, and implementation challenges.
Medicare beneficiaries with ALS will receive a new, no-cost outpatient multidisciplinary benefit (beginning Jan 1, 2027) that reduces out-of-pocket spending and improves coordinated access to PT/OT/speech/respiratory/nutrition/nursing and durable equipment coordination, likely improving quality of life and outcomes.
Patients in rural and mobility-limited communities will gain better access to ALS care through expanded telehealth options, reducing travel burdens and enabling more timely follow-up.
Patients, providers, and researchers will likely see faster and better-organized ALS clinical trials because providers get payment adjustments to offset trial-related costs and NINDS is tasked with identifying and addressing trial staffing/administrative bottlenecks, improving access to investigational therapies and trial capacity.
Taxpayers and the Medicare program face higher federal spending and budgetary pressure because expanding benefits and reimbursement increases program costs that may require offsets (higher taxes, premiums, or cuts elsewhere).
Medicare beneficiaries and taxpayers absorb costs because the benefit requires no patient cost sharing, shifting financial responsibility to Medicare and raising the risk of higher utilization and program costs.
Patients and the broader research community risk diverted research dollars and workforce attention toward ALS if overall budgets are not expanded, potentially reducing support for other conditions.
Based on analysis of 4 sections of legislative text.
Adds a Medicare outpatient benefit covering defined ALS-related services starting Jan 1, 2027, with a single-visit payment and periodic GAO payment reviews plus an NINDS report on trial challenges.
Creates a new Medicare outpatient benefit that covers a defined set of ALS-related services beginning January 1, 2027. The law defines which services qualify, requires a single-visit payment to providers for ALS care (paid in addition to other Medicare payments), sets a statutory payment schedule and adjustment rules, and orders periodic federal review of the payment amount. It also directs the National Institute of Neurological Disorders and Stroke (NINDS) to report within 90 days on problems running and staffing ALS clinical trials and to propose actions or legislative changes to improve those trials.
Introduced February 3, 2026 by Janice D. Schakowsky · Last progress February 3, 2026